116 related articles for article (PubMed ID: 8117608)
21. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
[TBL] [Abstract][Full Text] [Related]
22. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
24. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
26. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
27. Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: a study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Samantas E; Pectasides D; Pavlidis N; Kalofonos C; Klouvas G; Panoussaki E; Tsiakopoulos E; Poulakis N; Fountzilas G
Am J Clin Oncol; 1999 Feb; 22(1):87-93. PubMed ID: 10025390
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Skarlos DV; Samantas E; Briassoulis E; Panoussaki E; Pavlidis N; Kalofonos HP; Kardamakis D; Tsiakopoulos E; Kosmidis P; Tsavdaridis D; Tzitzikas J; Tsekeris P; Kouvatseas G; Zamboglou N; Fountzilas G
Ann Oncol; 2001 Sep; 12(9):1231-8. PubMed ID: 11697833
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
31. Ifosfamide, cisplatin and etoposide (ICE) combined chemotherapy with recombinant human granulocyte colony-stimulating factor support in small cell lung cancer.
Hastürk S; Kurt B; Kocabas A; Orüç O; Burgut R
J Chemother; 1997 Feb; 9(1):66-71. PubMed ID: 9106021
[TBL] [Abstract][Full Text] [Related]
32. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
36. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
37. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer.
Evans WK; Radwi A; Tomiak E; Logan DM; Martins H; Stewart DJ; Goss G; Maroun JA; Dahrouge S
Am J Clin Oncol; 1995 Apr; 18(2):149-55. PubMed ID: 7534977
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
Smith IE; Perren TJ; Ashley SA; Woodiwiss J; Forgeson GV; Yarnold JR; Ford HT
J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
